Understanding Social Factors, Medication, and Quality of Life in IBD
This study is looking at how social factors and medication use affect the quality of life for people with Inflammatory Bowel Disease (IBD). Researchers want to understand why some IBD patients, particularly Hispanic and Non-Hispanic Black individuals, might not get the full benefit from their IBD medications. The study will involve 400 IBD patients who will complete a survey. The main goals are to measure how well patients stick to their IBD medication plan and their health-related quality of life. You may be able to join if you are 18 or older, have a confirmed diagnosis of Crohn's disease, ulcerative colitis, or indeterminate colitis for at least three months, and can complete a survey in English or Spanish with basic computer skills. The current recruitment status is unclear.
- Study design
- This is an observational study, meaning researchers will collect information through a survey from 400 participants. It is not testing a new treatment, but rather observing current experiences.
- What's involved
- You would complete a single 20-minute survey upon joining the study.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Ruby Greywoode, MD · PRINCIPAL_INVESTIGATOR · Montefiore Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- IBD medication adherenceSingle 20 minute survey response, upon participant enrollment
The outcome of IBD medication adherence will be categorized by the adapted Hill Bone Medication Adherence Scale (HB-MAS). This part of the questionnaire consists of eight items used to assess patients' self-reported IBD oral medication adherence. Participant responses are scored on a scale from 1-4 (1 = All of the time; 2 = Most of the time; 3 = Some of the time; 4 = None of the time). Lower overall scores are associated with better medication adherence
- Health-related quality of life (HRQoL)Single 20 minute survey response, upon participant enrollment
HRQoL will be categorized based on responses to the NIH Patient Reported Outcomes Measurement Information System-29 (PROMIS-29). PROMIS-29 assesses each of 7 domains (Depression, Anxiety, Physical function, Pain interference, Fatigue, Sleep disturbance, Ability to participate in social roles and activities) using 4 questions with an additional Pain Intensity question. Participants' responses are scored from 1-5 (with the exception of the Pain Intensity Question which is scored from 0-10). The sum of each of the 7 PROMIS domains results in a raw score (from 4-20). There is no total score. Each axis forms its own score. PROMIS assessments use an Item Response Theory (IRT) based score called "Expected A Posteriori" or EAP scores, which are then transformed to a final T-score metric. As such, scores are mapped so that the values follow a normal distribution with a population mean T-score of 50 and a standard deviation of 10